Idiopathic membranous glomerulonephritis

This study tests a drug called surovatamig in 43 adults with primary membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The drug is given as a shot under the skin. Researchers want to see if it is safe and can reduce protein in the urine, which i…

This Phase 3 study tests a new drug called felzartamab in 180 people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. Felzartamab is a lab-made antibody designed to stop that attack. The study compares felzartamab to …

This study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…

This study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high pr…

This study tests an experimental drug called WAL0921 in 96 adults with kidney diseases that cause protein in the urine, including diabetic nephropathy and several rare conditions. Participants receive either the drug or a placebo as an IV infusion every two weeks for 14 weeks, th…

This study tests a new drug, povetacicept, against a standard treatment (calcineurin inhibitor) in 176 adults with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the new drug can put the disease into remission more safely a…

This Phase 2 trial tests whether adding belimumab to standard rituximab treatment helps more people with primary membranous nephropathy achieve remission. The study enrolls 58 adults with confirmed disease. Belimumab targets new immune cells, while rituximab depletes existing one…

This phase 2 trial is testing a new drug, budoprutug (also known as TNT119), in 45 people with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The study aims to see if the drug is safe and can help patients achieve remission. Participants receive…

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…

This early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidne…

This Phase 3 trial is testing a new gel called SNP-ACTH (1-39) against the standard drug rituximab in 148 adults with primary membranous nephropathy, a rare kidney condition. The goal is to see if the gel can better reduce protein in the urine and protect kidney function over 24 …

This study tests an experimental drug called ALXN1920 in 30 adults with primary membranous nephropathy, a rare kidney disease that can lead to kidney failure. Participants are at high risk for their disease getting worse. The study compares the drug to a placebo to see if it redu…

This study tests an experimental therapy called NKX019, which uses specially engineered immune cells from donors to target and calm overactive immune cells in people with lupus nephritis or primary membranous nephropathy. The trial involves 120 adults who have not responded to st…

This study tests a new drug, B007, against the standard treatment cyclosporine for people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 216 adults with confirmed disease and adequate kidney function will be randomly assigned to receive e…

This early-stage trial is testing a new drug called B007, given as a shot under the skin, for people with primary membranous nephropathy — a kidney disease where the immune system attacks the kidneys. The study will include 52 adults and will focus on safety, how the drug moves t…

This study tests whether adding finerenone to standard blood pressure medications can lower protein in the urine of people with primary membranous nephropathy, a kidney condition that can lead to kidney failure. About 116 adults will be randomly assigned to receive either fineren…

This study tests an experimental drug called AP1189 in people with a rare kidney condition called idiopathic membranous nephropathy, which causes severe protein leakage in urine. The trial includes 23 adults who are already on standard blood pressure medications. Participants wil…

This study tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with idiopathic membranous nephropathy, a kidney disease that raises clot risk. About 134 participants at high risk for clots but low risk for bleeding will receive either rivaroxab…

This early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cell…

This Phase 2 trial tests an experimental drug called SHR-2173 in 75 adults with primary membranous nephropathy, a kidney condition that can lead to kidney failure. The drug is given as an injection over several doses. Researchers are checking if it is safe and can help control th…

This study compares a newer targeted drug, obinutuzumab, against a standard treatment (cyclophosphamide plus steroids) for primary membranous nephropathy, a kidney disease that can lead to kidney failure. About 144 adults with moderate to severe protein in their urine will receiv…

This study tests a drug called obinutuzumab in 20 adults with a high-risk form of membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The goal is to see how quickly the drug lowers those harmful antibodies and whether it leads to remission. Partic…

This study compares different immune-suppressing drugs to treat a kidney disease called idiopathic membranous nephropathy. About 200 adults with high protein in their urine will receive one of several treatments. The goal is to see which drug works best to reduce protein leakage …

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check safety and how the body processes the drug, with a first look at whether it helps reduce protein in urine. P…

This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) for people with active kidney inflammation called glomerulonephritis. About 24 adults with membranous nephropathy or lupus-related kidney disease will receive either the new drug or a pla…

This study looks at whether measuring certain antibodies in the blood can help diagnose and monitor idiopathic nephrotic syndrome, a kidney condition that causes swelling and protein loss. Researchers will test blood samples from 100 adults with different forms of the disease and…

This study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…

This study is investigating whether certain autoantibodies, especially those targeting a protein called nephrin, play a role in nephrotic syndrome, a kidney condition that causes swelling and protein loss in urine. Researchers will analyze blood and kidney tissue from 50 children…

This observational study follows 500 adults with primary membranous nephropathy and nephrotic syndrome who are treated with rituximab or other monoclonal antibodies. Researchers aim to describe long-term disease outcomes and identify predictors of remission or progression. The st…

This study is investigating why some people with membranous nephropathy, a kidney disease, respond well to a treatment that depletes certain immune cells (B-cells) while others do not. Researchers will analyze blood samples from 86 patients and healthy volunteers to compare immun…

This study is testing a new ultrasound method to look at tiny blood vessels in the kidneys of people with nephritis (kidney inflammation). Researchers will use contrast-enhanced ultrasound and ultrasound localization microscopy to create detailed images of kidney blood flow. The …